MIR30D (MicroRNA 30d)

We show that elevated SNAIL protein levels induce the upregulation of SNAIL target genes that can be partially rescued by the addition of miR30d-5p. Our results highlight the key role for DICER1 and miRNA levels in modulating cell fate in breast cancer.

When AFP was integrated, diagnostic performance improved markedly across all comparisons: AUC = 0.97 (HCC vs. CHB), 0.84 (HCC vs. LC), and 0.91 (HCC vs. non-HCC). Combining circulating miR-21-5p, miR-34a-5p, and miR-30d-3p with AFP significantly enhances diagnostic accuracy for HBV-related HCC, supporting their utility as complementary non-invasive biomarkers for early screening.

The transfer-learned model ultimately achieves a high classification accuracy of 91.5% and a sensitivity of 92.2% on the clinical serum test set. We envision that the approach offers a cost-effective solution for high-accuracy liquid biopsy with limited samples.

AI-based radiomics demonstrated high effectiveness for predicting LVI, with RSs showing broad clinical applications. The addition of EV-derived miR-30d modestly improved predictability.

In conclusion, AVEN, as a promising diagnostic and prognostic biomarker in LUAD, affected tumour progression, immune infiltration and apoptosis resistance through the lncRNA-AC012236.1/hsa-miR-30d-5p-AVEN axis. These findings provided new insights into the pathogenesis of LUAD and highlighted potential therapeutic targets for improving patient prognosis.

Pathway enrichment and gene ontology analyses (miRTargetLink2.0, Enrichr) revealed interconnected regulatory networks linking miR-192, miR-16-5p, miR-143-3p, and miR-20a-5p to ITGB1; miR-143-3p/miR-145-5p to BRAF; and miR-16-5p and miR-30c/d to TIMP3. Collectively, these findings identify distinct miRNA-mRNA regulatory signatures-particularly the miR-192-5p-ITGB1/TIMP3 axis-as potential clinically relevant biomarkers that may contribute to racial disparities and disease progression in ovarian cancer.

These five microRNAs with significantly altered levels in plasma and tumoral tissue, could be good non-invasive CRC biomarkers candidates, enhancing screening, and supporting precision and individualized patient care.

Increased SOCS3 and decreased miR-30d-5p expression were observed in patients with NSCLC, indicating their involvement in tumor progression and immune disruption. The inverse correlation between these biomarkers suggests a regulatory interaction that may influence the JAK/STAT signaling pathway. These findings highlight the diagnostic and therapeutic potential of targeting the miR-30d-5p/SOCS3 axis in NSCLC.

Importantly, these effects could be reversed in vitro and in vivo by G6PD inhibitors, 6-AN, or siRNA. Our studies revealed CAPS1 as a novel regulator of G6PD and suggested that G6PD inhibition, such as 6-AN, represented a strategy for HCC therapy in patients with low CAPS1 expression.

miRNA signaling differs between the L and D phases of the LD cycle. miR-150-5p, targeting myb, bcl2, and cry1, can influence CRC progression in a phase-dependent manner.

This review summarizes recent insights into miRNA-autophagy interactions underlying drug resistance in thyroid cancer, emphasizing key miRNAs, including miR-125b, miR-144, miR-30d, and miR-9-5p. Understanding the complex regulatory networks connecting miRNAs and autophagy provides promising avenues for developing novel therapeutic strategies to overcome resistance in refractory thyroid cancer.

Employing an explainable machine learning approach, we established a 5-miRNA panel (miR-361-5p+ miR-130a-3p+ miR-27a-3p+ miR-30d-5p+ miR-193a-5p) with alpha-fetoprotein (AFP) for HCC screening. This combined panel demonstrated superior diagnostic performance compared to AFP alone (AUC: 0.924 vs. 0.794; p < 0.001) in distinguishing HCC patients in the testing and validation set, highlighting its potential as a promising minimally invasive screening method for HCC.